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Aim  and  methods:  We  conducted  this  case  study  in order to  test  how  health  system  per-
formance  could  be compared  using  the  existing  national  administrative  health  databases
containing  individual  data.  In  this  comparative  analysis  we used  national  data set  from
three countries,  Estonia,  Israel  and  Finland  to follow  the  medical  history,  treatment  out-
come and  resource  use  of  patients  with  a  chronic  disease  (diabetes)  for 8  years  after medical
treatment  was  initiated.
Results:  This study  showed  that several  clinically  important  aspects  of  quality  of care  as
well  as  health  policy  issues  of  cost-effectiveness  and  efﬁciency  of health  systems  can  be
assessed  by using  the  national  administrative  health  data  systems,  in  case  those  collecting
person-level  health  service  data.  We  developed  a structured  study  protocol  and detailed
data speciﬁcations  to  generate  standardized  data  sets,  in  each  country,  for long-term  follow
up  of  incident  cohort  of diabetic  persons  as  well  as  shared  analyzing  programs  to  pro-
duce performance  measures  from  the standardized  data  sets.  This stepwise  decentralized
approach  and  use  of anonymous  person-level  data  allowed  us  to  mitigate  any  legal,  owner-
ship,  conﬁdentiality  and  privacy  concerns  and  to  create  internationally  comparative  data
with  the extent  of  detail  that  is  seldom  seen  before.  For  example,  our  preliminary  perfor-
mance  comparisons  indicate  that  higher  mortality  among  relatively  young  diabetes  patients
in Estonia  may  be related  to considerably  higher  rates  of cardiovascular  complications  and
lower  use of  statins.
Conclusions:  Modern  administrative  person-level  health  service  databases  contain  sufﬁ-
ciently  rich  data  in details  to assess  the  performance  of health  systems  in  the  management
of  chronic  diseases.  This  paper  presents  and  discusses  the  methodological  challenges  and
the way  the  problems  wer
parability of  results.
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1. Introduction
International comparison of health systems has become
a popular media topic and powerful political tool inﬂuenc-
ing health policies and policy-makers. Such comparisons
and league tables commonly report quantitative parame-
Open access under CC BY-NC-SA license.ters based on aggregated statistics.
For example the mortality from heart disease is
a composite ﬁgure of different patient subgroups and
result of different treatment strategies, ranging from
r CC BY-NC-SA license.
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emergency revascularization in acute myocardial infarc-
tion to those treated with anticoagulants for ventricular
arrhythmia. From a health system perspective these patient
sub-populations are in need of very different medical
interventions and the problems or success of applying
diagnostic or treatment options cannot be revealed with-
out segregating the appropriate patient populations and
following these in time. Such questions are impossible
to solve by clinical trials or epidemiological studies with
strict inclusion and exclusion criteria, and this is where the
already existing administrative health care databases are
very important data sources.
During the last 10–20 years an increasing number of
international initiatives and projects have been launched
to make use of health data for cross-country research.
In addition to aggregate health system level approach,
disease-level analysis is gaining increased attention as it
takes the patient perspective into account. Due to aging
population and advances of medical technology the burden
is shifting from curative care to chronic disease man-
agement and there is an increasing number of patients
with multiple conditions, who seek support from differ-
ent providers. Thus following patients over time and in
different care settings becomes crucial in order to assess
the outcomes, effectiveness and efﬁciency of health care
interventions.
The international organizations (WHO and OECD among
others) have stressed the importance and potential of per-
formance comparisons and have introduced various types
of performance measures in their frameworks [1–3]. It has
also been recognized that comparative analysis of many
key performance measures (such as cost-effectiveness) in
international context requires patient-level data and suf-
ﬁciently long follow-up periods. However, there are not
much studies, experience or practical guidance how to use
the national health service databases and data systems
to solve the methodological issues in such exercises. For
example, the Health Care Quality Indicators Project of OECD
has experienced many difﬁculties in collecting comparable
data [2,3].
The rapid development of information technology in
health systems is creating large scale databases which
contain person-level administrative health data of large
populations and over long time periods. The experience
of using such data to study and improve health system
performance is growing, but is still in its early child-
hood. The advantages and disadvantages of administrative
health data can be debated [4–7], but much of its poten-
tial is unknown. It is of utmost relevant to study the
usability of already collected person-level administrative
health data in order to deﬁne, which relevant research
and policy questions can be answered and to develop reli-
able research methodologies for international comparative
research.
The aim of this study was to develop and test tools
for comparison of performance of health systems between
countries by using person-level administrative health
service utilization data.
The speciﬁc objectives were to explore what types of
personal-level data are available for performance mea-
surement at national level or for a large representative112 (2013) 110– 121 111
proportion of the population. In addition, our aim was
to reﬁne available indicators for performance evalua-
tion according to the data available and to develop data
processing algorithms accompanied with methodological
guidance on how to overcome the challenges for perfor-
mance measurement when using national administrative
health databases.
This study was conducted under the FP7-project
EuroREACH (www.euroreach.net) that aims to improve
access to and use of healthcare data for enhanced
comparative health systems analysis and performance
measurement. Within this project three participating
countries (Estonia, Finland and Israel) were considered to
have comprehensive person-level data with person IDs
available so that relevant health events of individuals can
be easily followed-up in time. Representativeness of data is
essential for international comparisons of national health
systems and the three countries involved have databases
with national coverage, which avoided any selection bias.
The focus was  decided to be on chronic diseases and dia-
betes was selected to be the example to be examined in a
case study.
2. Materials and methods
A case study was performed to examine how health
service utilization data from three countries with routinely
collected person level data can be used for performance
comparisons in diabetes. Representativeness for the whole
population was one of the key factors determining the
countries to be involved in the EuroREACH project case
study along with the length of time the data had been
collected in digital format.
Data were collected from Estonia (population 1.3 mil-
lion), Finland (5.2 million), and the member population
of Maccabi Healthcare Services, Israel (1.9 million, 25% of
the Israeli population). Key descriptives of these countries
are presented in Table 1, while summaries on the struc-
ture and organization of their health care systems are
available in the European Observatory on Health Systems
and Policies Health System in Transition (HiT) Reports
[8–10].
2.1. Study design and developing the study protocol
As it was decided a priori that diabetes was a topic
for the case study, the disease-based approach was
implicitly chosen as an approach. The disease-based
approach is known to be well suited for conducting
international comparisons as illustrated by the EuroHOPE
(www.eurohope.info) project, especially because it allows
to focus on patients’ episodes, i.e. their movements through
the certain speciﬁed components of the health system that
can be identiﬁed from all health systems.
Diabetes is a common chronic disease leading to severe
long-term complications if not treated adequately. For
example, the risk for major amputation is more than
sevenfold that among the nondiabetic population [11].
Regarding vascular complications, it has been noted in
Finland that coronary revascularization is less often per-
formed in diabetic patients and they experience more
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Table 1
Population, demographic and macroeconomic indicators of the three countries included in the study, 2005.
Estonia Finland Israel
Total population (millions) 1.34 5.26 7.18
Population 0–14 years (%) 15.2% 17.3% 28.3%
Population 65 and above (%) 16.5% 16.0% 9.8%
Population 80 and above (%) 3.1% 4.0% 2.6%
Male  life expectancy at birth (years) 67.3 75.8 79.3
Female life expectancy at birth (years) 78.1 82.7 82.2
Male  mortality rate per 1000 residents 28.8 9.3 5.9
Female mortality rate per 1000 residents 9.4 8.9 5.6
GDP  per capita (euros) 6739 30 005 15 270
Income inequality (Gini coefﬁcient) 0.37 0.26 0.39
Total  health expenditure per capita (US$ PPP) 771 2331 1975
73% 
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ources: Estonia [8], Finland [9], and Israel [10].
mergency hospital admissions before the operations than
atients without diabetes [12]. As time is important in mea-
uring the outcomes of diabetes we decided to employ a
ohort approach in order to: (i) describe diabetes treatment
atterns over time; (ii) evaluate the health care resource
se; (iii) map  the occurrence and timing of distal outcomes,
.g. mortality and major complications; (iv) relate the out-
omes to whether the preventive and curative measures
ere provided.
To make the comparison possible a study protocol
ith detailed data deﬁnitions was developed to deﬁne
he study populations and speciﬁc indicators to be eval-
ated. Thus the ﬁrst step was to agree and adapt the
umerous potential study questions to the content, avail-
bility and access of person-level health data in the three
ountries.
.2. Estonian data
Estonia has a national health insurance system managed
y the Estonia Health Insurance Fund. The administra-
ive database of this Fund includes electronic billing data
rom year 2000 onwards for all insured population (1.3
illion) of the country. Each person has a unique per-
onal code in the database and delivery of any in-patient
r out-patient health care services (prevention, diagnostic
nd treatment) and use of prescription medicines can be
dentiﬁed together with information on main diagnoses,
o-morbidities (ICD-10) and provider as well as dates of any
ervices provided and costs paid by the insurance. Whereas
here are no functional disease registries in Estonia (except
o the Cancer Registry) only data from the administrative
ealth service database of the Estonia Health Insurance was
able 2
tudy populations of diabetes patients according to age and gender.
Age Number of diabetes patients Females 
Estonia Finland Israel Estonia 
Total 3016 18 882 6452 60% 
0–17  51 554 70 1.3% 
18–44  290 2035 1178 7.6% 
45–64  1397 8494 3211 42% 
65+  1278 7799 1993 49% 78% 68%
4.3 7.1
used for this case study and no linkage with other databases
was  neither necessary nor possible.
The database in Estonia is owned by the Health Insur-
ance Fund and data for research purposes has to be applied
from the Fund by presenting the study protocol. While
there is no fee for data retrieval, it can take consider-
able time to obtain the data requested. The person-level
data extracted for research purposes is pseudonymized,
and according to the national legislation no approval
from the Ethics Committee or the Data Protection Agency
is required for studies, if the study subjects cannot be
identiﬁed.
2.3. Finnish data
Finland has a universal health care system that has dual
public funding from municipalities (tax-based) as well as
from national health insurance (based on tax-like insur-
ance fees). More than 300 municipalities in Finland are
legally responsible for provision of health care for their resi-
dents. Specialized care is provided by hospital districts that
are owned by municipal federations. In addition to public
health care there are occupational and private health care
components in the health care system that provide ser-
vices additional to the public system and whose fees for the
patients have partial subvention from the national health
insurance. The costs of prescribed medication are at least
partially covered by health insurance.
Finland has a comprehensive system of medical reg-
isters and administrative databases, where person-level
data are collected and can be linked using a unique
national personal identiﬁcation number. For the purposes
of the current study, a linkage-based research database
Males
Finland Israel Estonia Finland Israel
48% 50% 40% 52% 50%
2.7% 1.3% 2.3% 3.1% 0.9%
11% 22% 13% 11% 16%
37% 44% 52% 52% 56%
49% 32% 33% 34% 27%
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of Finnish diabetic patients was used [13]. In brief, the
Finnish Diabetes database contains information on more
than 800 000 potentially diabetic patients since the 1960s
from virtually all relevant nationwide registers includ-
ing insurance schemes and medical registers. Since 1996
diagnoses have been recorded using the ICD-10 classi-
ﬁcation. This database is administered by the National
Institute for Health and Welfare. The maintenance of
this research database is based on agreements between
National Institute for Health and Welfare and its partners
and permissions are needed from the partner organiza-
tions.
2.4. Israeli data
Israel has a national health insurance system, run by
four non-proﬁt health plans that receive health insur-
ance funding according to capitation formula and provide
the same broad beneﬁt package to all enrollees. Mac-
cabi Healthcare Services covers 25% (1.9 million) of the
Israeli population. Maccabi’s patient information systems
cover visits to hospitals, physicians and other health pro-
fessionals, prescription drug purchases, laboratory testing
(including results) and imaging studies. Hospital diagnoses
are reported as ICD-9 codes; physician diagnoses are coded
either as ICD-9 codes or according to a system of local
codes. In addition to health care service use, the data
collected by Maccabi Healthcare Services includes infor-
mation on patient health status (e.g. smoking, bodyweight,
blood pressure). For this case study no data linkage was
required or done with Israeli data, because the health
service database of Maccabi Healthcare Services included
all data necessary for this international comparison.
In Israel the database is owned by the Maccabi Health-
care Services and can be used for research purposes in
line with the objectives of the organization. Any research
projects using person-level data have to be approved by the
Ethics Committee of the organization. Because of data pro-
tection considerations no person-level data can be given to
researchers outside Maccabi Healthcare Services and the
analysis of data for this case study was performed in-house.
2.5. The incident diabetic cohort using medication
purchases
Based on initial discussions it was quickly established
that the easiest and most compatible deﬁnition for incident
diabetic persons could be achieved using medication data
that were very similar across the participating countries. Of
course, this deﬁnition excluded diabetic persons that did
not use antidiabetic medication, but it guarantees that the
study population does not include non-diabetic persons.
In order to have the longest possible follow-up time, we
deﬁned an anonymous cohort of “newly treated (incident)
diabetes patients” in the participating countries as those
starting to use diabetes medication in the period from 1
July 2002 to 30 June 2003, and not purchasing any antidia-
betic medication within 365 days prior to the ﬁrst purchase
(index date).
Start of diabetes treatment was deﬁned as at least two
separate purchases of antidiabetic medication (ATC group112 (2013) 110– 121 113
A10) on two different dates inside a 180-day period: ﬁrst
purchase during 1 July 2002 and 30 June 2013 and second
purchase within 180 days from the ﬁrst purchase (index
date). We  further divided the patients into “probable type
1 patients” and “other diabetes patients”. The patients with
type 1 diabetes were those, who  had two insulin purchase
dates within ﬁrst 180 days and no sulphonylureas pur-
chased in ﬁrst year. The rest of patients were deﬁned “other
diabetes patients” irrespective, whether they started to use
insulin later or not.
2.6. Data deﬁnitions and query speciﬁcations
It was decided that the patients in the incident cohort
(deﬁned above) would be followed from the index date
of purchase of the ﬁrst antidiabetic medication until 31
December 2011 or death or migration.
However, as data nomenclature and availability in
administrative databases are inﬂuenced by the payment
mechanisms as well as data accuracy and reliability, avail-
able datasets deﬁne what questions we  can raise and the
analysis of data shows what questions we can answer with
satisfactory accuracy. The following steps were taken to
ensure the quality and representativeness of data: (i) care-
ful preliminary exploration of the data; (ii) agreement on
the deﬁnitions and classiﬁcations; (iii) assessment of the
comparability of data between different sources; (iv) create
data speciﬁcations for the common dataset; (v) agreement
on how to measure relevant indicators of quality, outcome
and costs; (vi) consideration on the limitations of data anal-
ysis, i.e. the extent of bias.
We used network approach for data analysis with
three face-to-face meetings, where national differences
in data organization and collection were discussed in
detail. Based on discussions during these meetings a con-
sensus on contents of base and follow-up datasets was
obtained. The common data structure is presented in
Appendix A. It contains patient demographic data and
use of hospital and out-patient health care services as
well as use of medicines and laboratory tests. National
database-speciﬁc codes were applied to identify the ser-
vices and outcomes of interest and common deﬁnitions
were created for out-patient visits, hospital stays and day
treatments. Differences in used classiﬁcations between
countries posed some challenges. Semi-automatic map-
ping between ICD-9 and ICD-10 diagnoses was relatively
easy, but procedure classiﬁcations required more manual
work. Therefore separate indicator variables were created
for coronary revascularizations, lower limb amputations,
end-stage renal disease, cataract surgeries, retinopathy,
myocardial infarction, stroke, heart failure and ischemic
heart disease. For other classiﬁcations, drug data could
be handled by using mapping from generic drug names
to ATC-classiﬁcation in Israeli data (Estonia and Finland
had ATC-classiﬁed drug data). Most challenging issues
were classiﬁcations and deﬁnitions that were related to
the structure and coverage of health (insurance) systems,
such as long-term, elderly and mental health care as well
as the medical specialty codes. The only option to deal
with these issues was that each center processed their
own national data using all (tacit) information they had
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nd created their datasets according to the agreed general
data-independent” speciﬁcations into the deﬁned format.
his approach has some similarities to OMOP (Obser-
ational Medical Outcomes Partnership) Common Data
odel (omop.fnih.org).
.7. Performance measures
Data deﬁnitions were aimed to be as comprehensive
s possible, but were anyhow designed keeping in mind
ertain different aspects of performance that were consid-
red interesting. In the selection of indicators of interest we
ollowed the recent work in OECD [14] and the EUBIROD
www.eubirod.eu) project. The list of disease-speciﬁc out-
ome, quality and cost indicators included:
. All-cause mortality in patients with diabetes.
. Outcomes and complications of diabetes treatment –
(cumulative) proportion and frequency of patients’ hos-
pitalized and treated for coronary revascularizations,
myocardial infarction, stroke, lower limb amputations,
end-stage renal disease (dialysis or with a kidney
transplant), and/or eye complications (retinopathy or
cataract).
. Visit frequency and proportion of patients visiting pri-
mary care doctors and/or specialists, calculated as no
gap more than 365 or 730 days, and not visiting a doctor
during 8 years.
. Extent and consistency of pharmaceutical care as pro-
portion of diabetic patients using insulin and different
oral antidiabetic drugs regularly (at least 2 separate pur-
chases per year) as well as proportion of patients using
statins, antihypertensives and antidepressants.
. Regular monitoring for hyperglycemia (HbA1c), choles-
terol (LDL) and regular testing for microalbumin or
albumin/creatinine, calculated as no gap more than 365
or 730 days, and never tested during 8 years of follow-up.
. Cumulative cost-of-treatment of the diabetes patient
cohort and use of resources, presented as cumulative
bed-days, doctor visits and medication purchased per
1000 patient-years.
. Unit costs as average (cost weighted) use of resources
per patient treated.
. All these indicators were based on data that should be
comparable between countries. In addition, patient cen-
tered indicators such as health behavior, functionality
and quality of living would have been interesting, but
no (comparable) data were available.
.8. Data analysis
For the actual data analysis, more speciﬁc aims were
eﬁned and the study questions were assigned to the three
enters. The ﬁnal list of data speciﬁcations (see Appendix
) were used to develop common data scripts for the sta-
istical programs R, Stata and SAS. Each center developed
nd coded the respective algorithms which were then dis-
ributed to the other centers. After ﬁxing the datasets each
enter ran the common distributed programs themselves
nd no person-level data was shared or shipped abroad.
y using identical data structure and the same scripts for112 (2013) 110– 121
analysis we  ensured that the analysis was performed
exactly the same way  by all three partner organizations.
To increase the comparability of data we performed the
inter-country analysis adjusted or stratiﬁed by gender and
age or according to risk factors known, where appropri-
ate. For example, survival analysis was used to evaluate
the diabetes-attributed additional mortality by comparing
the mortality of diabetes patients to the age and gender
adjusted national mortality rates of the three countries.
We present here only background factors and certain
preliminary results of our comparisons. More detailed
analyses with sophisticated statistical methods will be
published separately.
3. Results
3.1. Protocol for performance measurement
The major outcome of the study was  the abstraction of
the process of working to provide pragmatic results using
real datasets from three countries. More speciﬁcally, the
following steps were taken to develop common analytical
methods and their application on a pre-processed dataset
in each of the three countries:
1. Agree on study design and identify the study population.
2. Reﬁne data speciﬁcations in order to export data from
health databases.
3. Pre-process data into standardized format required in
the analysis.
4. Specify the measures for performance.
5. Develop common analytical programs.
6. Conduct analysis at each site using the standardized pro-
grams.
7. Pool the results and report.
The structured study protocol and detailed data speciﬁ-
cations made it possible to generate standardized data sets
in each country for long-term follow up of incident cohort
of diabetic persons as well as shared analyzing programs
to produce performance measures from the standardized
data sets.
The scripts and analytical programs developed for this
study can be made available to researchers who have access
to similar person-level health data (or part of it), and are
able to process their data into the format described in
Appendix A. This makes it possible for anyone to perform
their own  analysis in a comparable way.
3.2. Selected examples of diabetes care and treatment
outcomes
To brieﬂy illustrate the extent and detail of comparative
data available, Table 4 presents a selection of crude quality
of care measures and Table 5 some outcome and utilization
measures. The indicators in Table 4 describe the continuity
of care, which is important in the treatment of every patient
with a chronic disease. The diabetes patients in Estonia are
not as frequently monitored for glycohemoglobin, choles-
terol or albuminuria as compared to the established quality
indicators and as compared to the diabetes patients from
R. Kiivet et al. / Health Policy 112 (2013) 110– 121 115
Table 3
Data availability for diabetes studies in the three health systems.
Estonia Finland Israel
Type of diabetes No Yes Yes
-  Continuous insulin treatment Yes Yes Yes
Process data
- Primary care outpatient visits Yes No Yes
-  Specialists visits (in hospital) Yes Yes Yes
-  Emergency department visits Yes Yes Yes
Prescriptions (drug purchases)
- Antidiabetic medication Yes Yes Yes
-  Statins Yes Yes Yes
-  Antihypertensives, i.e. ACE/ARB, calcium channel and beta-blockers Yes Yes Yes
Laboratory services
- Type and count Yes No Yes
-  Results No No Yes
Hospital inpatient stay
- Admissions (count, type of hospital) Yes Yes Yes
-  Length of stay Yes Yes Yes
-  Main diagnosis Yes Yes varies
-  Procedures Yes Yes Yes
Outcomes/complications
-  Coronary revascularizations Yes Yes Yes
-  Lower limb amputations Yes Yes varies
-  Myocardial infarction Yes Yes Yes
-  Stroke Yes Yes Yes
-  End-stage renal disease Yes Yes Yes
-  Retinopathy, cataract Yes Yes Yes
Costs
-  Diabetes only Yes Yes Yes
-  All treatment costs Yes Yes Yes
-  Hospital, out-patient, medicines Yes Yes Yes
Availability of data to assess health system performance domains
Health status No No +/−
Non health care determinants of health +/− +/− +/−
Health care system performance 
Health  system design and context 
Equity  
Israel. Using the cohort approach it was possible to follow
what happens to patients after diagnosis of diabetes. For
example, the unadjusted survival on “newly diagnosed dia-
betes patients” in Estonia was considerably lower than
in Finland and Israel (Table 5). Note that time was not
Table 4
Quality of diabetes care indicators, describing the continuity of care during 8 years
data  was available.
Every year (no gap more than 365 days) Every sec
Blood test for HbA1c (glycohemoglobin)
Estonia 4% 20% 
Israel  27% 72% 
Blood  test for LDL cholesterol
Estonia 1% 6% 
Israel  29% 77% 
Urine  test for albumin/creatinine
Estonia 0.5% 1% 
Israel  3% 38% 
Visit  to any physician
Estonia 73% 94% 
Israel  86% 95% 
Visit  to primary care physician
Estonia 44% 83% 
Israel  85% 93% 
Visit  to endocrinologist
Estonia 3% 9% 
Israel  2% 5% Yes Yes Yes
Yes Yes Yes
No Yes +/−
calculated for calendar years, but individually for 8 con-
secutive follow-up years (or until death).The dynamics in the pharmaceutical treatment of dia-
betes patients (Table 5) provides also very interesting
ﬁndings – rate of transfer to insulin treatment is twice as
 of follow-up for Estonia (n = 3016) and Israel (n = 6452), where respective
ond year (no gap more than 730 days) Never tested or visited
17%
6%
25%
1%
40%
8%
0.1%
1%
2%
1%
40%
50%
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Table 5
Selected outcomes and service measures as provided to the diabetes patients during each of the 8 years of follow-up.
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
Study population alive at the end of year (%)
Estonia 96% 93% 89% 86% 82% 79% 75% 72%
Finland 98% 95% 92% 89% 86% 83% 80% 78%
Israel  98% 96% 94% 92% 90% 88% 86%  83%
Hospitalized for myocardial infarction, males 45–64, rate per 1000 per year
Estonia 16 13 12 23 9 15 19 12
Finland 5 8 6 8 6 6 6 5
Israel  6 6 8 7 4 8 5 3
Revascularization, males 45–64, rate per 1000 per year
Estonia 26 10 20 27 20 24 27 26
Finland 11 10 11 12 11 11 11 9
Israel  12 10 8 3 10 6 3 2
Stroke,  females over 65, rate per 1000 per year
Estonia 25 31 21 16 27 26 27 31
Finland 23 28 21 23 16 19 20 21
Israel  2 3 3 5 6 6 5 2
Proportion of patients using insulin at the end of year
Estonia 14% 15% 17% 21% 24% 27% 31% 32%
Finland 15% 14% 16% 18% 21% 25% 28% 31%
Israel  9% 7% 8% 9% 11%  14% 16% 19%
Proportion of patients using statins at the end of year
Estonia 6% 7% 9% 11% 13% 16% 20% 23%
Finland 32% 37% 41% 44% 48% 51% 54% 55%
68%
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igh in Estonia and Finland as compared to Israel, a ﬁnding
hich is difﬁcult to attribute to anything else than thera-
eutic traditions.
In our attempt to assess efﬁciency, the preliminary com-
arisons on resource and costs of diabetes care revealed
hat the annual use of health care services seemed rather
table in time-series in each of the countries. However,
here were signiﬁcant differences in the levels and compo-
ition of resource use between countries: the cumulative
robability of being hospitalized, as expressed in hos-
ital episodes per 1000 patient-years, appeared to be
lmost twice as high in Estonia and Finland as com-
ared to Israel (Table 6). However, the average length
f stay in Israel was considerably higher compared to
inland, thus equalizing the total use of bed-days. A more
etailed analysis stratiﬁed by age, gender and cause of
ospitalization will provide further information about the
easons for the observed differences in cumulative use of
esources.
In Estonia the costs for pharmaceuticals were as high
s in-patient costs, both accounting approximately 40% of
otal costs while in Finland the percentage of drug costs
ave been estimated to be 25%. The average total direct
ealth care costs per diabetic patient doubled from 800 eur
o 1500 eur in Estonia during the 8 year follow-up whereas
n Finland the increase was more modest, some 26% (from
500 eur to 4400 eur).
We  were able to show considerable inter-country dif-
erences in the utilization of health services for the control
f diabetes, as well as in prevention of diabetes complica-
ions. For example, our performance comparisons indicate
hat higher mortality among relatively young diabetes
atients in Estonia may  be related to considerably higher
ates of cardiovascular complications and lower use of
tatins. 71% 73% 74% 75%
3.3. Comparability
The databases covered all health service data for the full
respective populations and were thus representative for
Estonia, Finland and Maccabi Healthcare. The main demo-
graphic difference between the three countries was  that
the Israeli population was relatively young (see Table 1)
and the proportion of persons over 65 was  less than 10% in
Israel [10], whereas it was  16% in Finland [9] and in Estonia
[8] in 2005.
The national demographic differences were reﬂected
also in the study populations of diabetes patients, where
persons over 65 accounted for a considerably higher pro-
portion in Estonia and Finland as compared to Israel
(Table 2). As well, the gender distribution was  uneven
in Estonia, where women  accounted for 60% of diabetes
patients. The age and gender differences had to be taken
into account and, to study the incidence of major compli-
cations we  stratiﬁed the analysis by gender and major age
groups (0–17, 18–44, 45–64 and over 65 years).
In general, differences in the case-mix of the patient
populations are considered to be a source of bias for per-
formance comparisons. As the outcome and processes for
each patient depend on the baseline characteristics of the
patient, the care providers treating more severe patients
tend to have worse outcomes (e.g. mortality) compared to
the ones with lighter case-mix even if the quality of the
treatment had been the same. A common approach in per-
formance comparisons is to classify observed variation in
outcomes into three components: patient-speciﬁc compo-
nent, provider-speciﬁc component and random (residual)
component. Often the main interest in performance com-
parisons is in the provider-speciﬁc component and the
aim is to adjust for the uninteresting (obvious) variation
in the performance, i.e. to eliminate the patient-speciﬁc
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Table 6
Total use of resources for in-patient care (any cause) for the total study cohort during the follow-up of 8 years.
Estonia Finland Israel
Total nr of patient-years 20 702 134 583 37 513
8.03) Hospital episodes per 1000 patient-years 386 
Nr  of bed-days per 1000 patient-years 3074 
Average length of stay (95% CI) 8.0 (7.9–
component. Usually it is assumed that a suitable (hierarchi-
cal) statistical model or matching technique can be used to
produce “risk-adjusted” comparable outcomes [15]. Unfor-
tunately, such models can seldom be used to deal with the
challenges related to availability and contents of (compa-
rable) data.
Comparison of differences in data availability is pre-
sented in Table 3. In short, Israeli data were most
comprehensive whereas laboratory test results were not
collected in Estonia and Finland did not have data on lab-
oratory services or on the utilization of outpatient visits
in primary care. However, the coverage of Finnish data on
long-term and psychiatric care was better as those were
recorded independently of any insurance system.
To enhance comparability we used national classiﬁ-
cations and codes to cross-tabulate the case and event
deﬁnitions, as described brieﬂy under Methods section
and listed in Appendix A. However, despite our standard
deﬁnition of diagnoses and services, we assumed consid-
erable variation in the identiﬁcation of events across the
countries. This variation was due to differences in the
demographic structure of the study populations, due to
differences in diagnosis and procedure coding practices,
differences in the calibration of laboratory measurements
and sensitivities arising from the methodologies used.
3.4. Measurable domains of performance indicators
One of the aims of our study was to test, what aspects
of health system performance can be addressed and what
research questions answered by using the administrative
health data available in the participating countries. Elec-
tronic health records in Maccabi Healthcare could provide
information on person-level health status and health deter-
minants (i.e. smoking and body weight) whereas the
databases in Estonia and Finland were based on less
detailed abstractions of the patient administration sys-
tems. The data available for calculation of performance
measures as described under Methods are listed in Table 3
and described according to the main domains of interest.
These domains represent the key health system
domains outlined by the EuroREACH framework
(www.euroreach.net) which are based upon the
OECD Health Care Quality Indicators Framework [3]
representing:
1. Health status: denotes society’s broader health as inﬂu-
enced by health care and non-health care factors.
2. Non-health care determinants of health: denotes the
mostly society-wide, non-health care factors that also
inﬂuence health.360 190
2018 1665
5.6 (5.58–5.63) 8.8 (8.7–8.83)
3. Health care system performance: denotes the processes,
inputs, and outcome of the health care system as well as
its efﬁciency and equity.
4. Health system design and context: this denotes per-
tinent country and health system policy and delivery
characteristics, which will inﬂuence the health system
in terms of its costs, expenditure and utilization patterns
that must be considered in order to contextualize the
ﬁndings of the health performance tier.
5. Equity: this considers equity of health outcomes across
the population of interest.
In the list of performance measures that potentially
could be evaluated, some could be easily calculated in the
current study (e.g. typical outcome indicators, mortality,
complication rates) and a few were impossible to assess
(equity, wellbeing). The rest were indicators, where data
comparison could be done, but the interpretation of results
was either difﬁcult or not very informative (e.g. costing).
As expected, we had most comprehensive information
about the process measures (prescribed medications and
different health services) and the performance of health
care system in the management of diabetes could be com-
pared relatively well (Table 3). At the other end – we were
lacking data for evaluating the health needs of the study
populations, i.e. data about health status (disability) and
quality of life, as well as socio-economic and lifestyle health
determinants, and thus we  had rather limited possibilities
to adjust the use of services according to the health needs.
Among the most challenging to interpret were the
measures related to costs (leading to difﬁculties to assess
cost-effectiveness and efﬁciency). The main problem was
that (with the exception of antidiabetic medication) it was
not possible to distinguish between the diabetes-related
services, activities and costs and the total care provided
to patients, who usually have multiple chronic disorders.
In addition, due to lack of common service deﬁnitions and
input price conversion problems a meaningful comparison
of costs between countries and over time is difﬁcult [16].
The ﬁnding in our study was that in order to approximate
costs of service utilization, one could use a crude classiﬁ-
cation of intermediate services (e.g. bed-days, outpatient
visits, major procedures) with corresponding cost weights
for each class of service. However, it was beyond the scope
of the present study to develop such cost weights.
4. DiscussionThe comparative analysis using person-level admin-
istrative data on the use of health services in the
three countries demonstrated the possibility to obtain
unique, relevant and sufﬁciently reliable information on
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erformance parameters such as the outcome, quality and
tilization of the respective health systems. Our study
howed that existing administrative databases can be used
o answer speciﬁc research questions by using a stepwise
ecentralized approach for data analysis, without creat-
ng new and additional databases or networks. We  mainly
ocused on one important dimension in performance mea-
urement: efﬁciency (i.e. the outcomes and resource use)
 to illustrate the methodological aspects of the process in
onducting international comparisons.
We emphasize, that this case study was not designed
o evaluate every aspect of diabetes care, but to evaluate
he usability and usefulness of person-level administrative
ata to monitor the medical history of a chronic patient. We
o not claim that the deﬁnition of our study cohorts based
n the use of antidiabetic medication included all persons
ith incident diabetes and that it was equivalent to clinical
iagnosis of diabetes. However, this approach did cap-
ure all diabetic patients, who were put on pharmaceutical
reatment in the study countries. Thus the study was not
pidemiological study of diabetes, but we investigated the
se of health services, where the patients treated in similar
ay were followed to evaluate outcome and resource use.
iabetes was used as an example and the same approach
an be used to monitor performance of health systems in
ther chronic diseases and patient populations.
Comprehensive performance assessment of health sys-
ems in management of chronic diseases calls for nationally
epresentative data on incidence and prevalence over time
nd utilization of preventive and curative health services at
erson level in order to link the health outcomes to treat-
ent provided and the resources used. The most obvious
dvantages of administrative health data are that it cov-
rs representative populations and long time-frame and is
lready collected. In fact, one of the major strengths of using
inkable administrative databases over other methods of
ata collection is that those provide data for long-term
ollow-up of patients, which is essential for drawing solid
onclusions on distant outcomes of any interventions,
hether preventive or curative.
However, as our experience illustrates, there is no way
o directly access and use patient-level administrative
ata for international comparative research, In addition to
egal and ownership issues it should be emphasized, that
dministrative health data is until now not collected and
rganized for the purposes of performance analysis. Thus
ne has to follow the traditional steps from deﬁning the
esearch questions and identifying the data needs accord-
ng to the availability of data.
At least four conclusions can be drawn from the cur-
ent study. The ﬁrst of the key messages from the study is
 information is not ready for use for performance assess-
ent, but has to be generated ad hoc following a common
rotocol and analyzed in a comparable way. It is essential
hat also the ﬁrst steps of data preprocessing are carefully
onducted as it is necessary to guarantee the technical qual-
ty of the comparative analysis. Such step is actually one of
he most time-consuming phases of this kind of research.
Secondly, identifying disease-speciﬁc populations and
alculating incidence rates is a major result of our study, as
t was done with the help of secondary data from existing112 (2013) 110– 121
databases designed to collect ﬁnancial or administrative
data. We  were able to do this, because the disease we
studied (drug treated diabetes) had complete reimburse-
ment coverage in the three health systems involved. This
approach would not provide similar comprehensive results
with patient populations, who have any reason or incen-
tives to use services or medicines outside the system or in
countries, where full coverage of insurance is not available.
Thirdly, we were able to create comparative data for a
considerable number of indicators on quality of diabetes
care. Despite these evidence-based indicators had been
proposed for international comparison, the lack of avail-
ability of data had not made it possible to make use of
these to the extent of detail that the data produced in this
case study will allow. In addition, by working with actual
patient-level data we  could reﬁne the existing measures
and even propose some “new ones” such as regular use of
medication and event-free time from the start of diabetes
treatment.
The fourth lesson learned is to handle the issues of pri-
vacy and data protection, which are topical questions in
health data analysis. In order to mitigate any legal, security,
ownership, governance, conﬁdentiality and privacy con-
cerns we decided neither to create a separate central data
warehouse nor to share the original data. We  avoided these
problems by using anonymous data and by performing the
data analysis nationally in-house by the institutions own-
ing the data. In addition to avoiding the legal and privacy
concerns, it allowed the data holders to retain physical and
logical control of their data and eliminated the need to cre-
ate, maintain, and secure access to central data repositories.
Our approach is similar to the concept of distributed
health data networks [17,18], but our approach does not
require development of dedicated software or consider-
able stakeholder engagement to maintain the research
infrastructure. In addition and instead of creating and
maintaining single-purpose health data repositories (i.e.
disease registries), where analysis options are limited to the
extent of detail as deﬁned in the repositories’ architecture,
the existing person-level administrative health databases
can be used to carry out ad hoc comparative performance
analysis to answer a wide variety of research questions.
It should be emphasized, that an unconditional pre-
requisite to evaluate health system performance with the
help of person-level data is the availability of the unique
personal identiﬁer, which should be pseudonymized for
research purposes. Within the three countries included
in this study, namely Estonia, Finland and Israel, it was
possible to deterministically link individual-level data so
that long-term follow-up became feasible. Such unique
personal ID is not used or even legally allowed in some
countries, which seriously undermines the opportunities
for trans-European performance evaluation. As well, the
legal framework in place in the three countries made it
possible to use anonymous person-level data for research
purposes, which unfortunately is not the case in many of
the European countries.There are many papers discussing on how to compare
quality or efﬁcacy by using an “ideal” dataset, but such ideal
data does not exist and our study illustrates the efforts to
maximize information from the data already collected and
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available for use. For example, in ideal terms we would like
to calculate cost per QALY, but this information is not col-
lected in real life. Instead, we calculated event-free time
and costs related to keeping patients free of complica-
tions. Our study provided information on what research
questions are reasonable to ask and what questions can
be reliably answered in case national health person-level
health service data is collected.
Despite the many merits, the administrative data used
in this study have its limitations, which have to be taken
into account while interpreting the results. Namely, the
administrative data are usually collected for statistical and
ﬁnancial record-keeping purposes and thus the accuracy
of clinical information included in these data is secondary
and cannot be taken as granted. In addition, these data,
even if collected at person-level, do not usually contain
information on health status or lifestyle determinants of
health, which all contribute to the health needs of the per-
son and inﬂuence the use of services. Thus administrative
data cannot provide answers to all relevant research ques-
tions in health systems performance assessment, especially
the inferences on causality remain challenging. Moreover,
the data do not cover persons, who do not use health ser-
vices for their speciﬁc health needs. For a more complete
discussion on the advantages and disadvantages of admin-
istrative data see Roos et al. [4,5], Smith et al. [6], and Sund
et al. [7].
It is also important to recognize, that for interpre-
ting data on quality of care and performance of providers
or health systems in the treatment of most chronic dis-
eases (incl. diabetes), the patient-related factors, especially
adherence to treatment and implementation of lifestyle
changes, are at least as important as proper use of medi-
cal interventions and services, including pharmacotherapy.
In our study we chose to use age and sex stratiﬁcation to
map  the main distal outcomes of diabetes care, but risk-
adjustment could be done as well if considered relevant.
While the datasets in this study provided various
types of outcome indicators, the determination of disease-
speciﬁc costs turned out to be a challenging task. In chronic
diseases such as diabetes it is not clear in which case the
health service is related to diabetes. A complete tabulation
of diagnosis codes could be used for this task, provided that
the coding practices are similar. Furthermore, the lack of
common service deﬁnitions (e.g. hospital admission cate-
gories, primary care, medication) made it difﬁcult to value
the individual health service contacts. One possible solu-
tion could be to use a crude classiﬁcation of intermediate
services (e.g. bed-days, outpatient visits, major procedures)
with corresponding cost weights for each class of service.
We were also lacking data for evaluating the health
needs of the study populations, i.e. data about health status112 (2013) 110– 121 119
(functionality and disability) and quality of life, as well as
socio-economic and lifestyle health determinants. Some of
these data did exist in some countries, such as socioeco-
nomic data in Finland and BMI  and smoking status in Israel.
However, our primary aim was  not to list all non-available
data in each country but to focus on comparable data. Yet
it is important to demonstrate what kind of data should be
feasible to collect in the future and highlight the beneﬁts of
coordination s on data collection across the countries. One
major deﬁciency still remains as the main obstacle for pro-
viding suitable data for performance comparisons in many
countries: the lack of nationwide personal identity codes.
5. Conclusions
The main conclusion from our study is that exten-
sive international performance assessment can be achieved
with the help of detailed data speciﬁcations to generate
standardized data sets and by developing common analyz-
ing programs to produce performance measures from the
standardized data sets.
The main challenges in this study were related to
development of deﬁnitions that would represent the best
compromise taking into account the differences in the
contents and classiﬁcations of available data between the
countries. That would not have been possible without
our study group meetings in which the (data) experts
could discuss the pragmatic problems, data validity issues
and technical details of their data sets. Unfortunately, the
suggested protocol in this paper covers only the clearly sys-
tematic parts of the process, which means that a number of
context-speciﬁc issues still need to be addressed by anyone
following our protocol.
For the purposes of this study we developed a stepwise
decentralized approach and used anonymous person-level
data, which allowed us to mitigate any legal, ownership,
conﬁdentiality and privacy concerns and to create interna-
tionally comparative data for calculation of a considerable
number of performance indicators with the extent of detail
not achieved before.
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Appendix A. List of variables for diabetes study
Variable name Type Label
Patient’s demographic data ﬁle
pt id 5 Num Patient masked ID
birth dt 8 Num Patients birthdate (DATES as: days since 01.01.1960)
death  dt 8 Num Patients death date
drop  dt 7 Num Drop-out day or 31 December 2011
last  dt 7 Num Last date of contact (drug purchase, hospital episode, physician visit etc.)
gender  6 Num 1-male; 2-female
ind1 dt 7 Num First qualiﬁed diabetes drug purchase (index date)
ind2 dt 7 Num Second qualiﬁed diabetes drug purchase in 180 days
trt  ins 7 Num Number of insulin purchase dates (ATC = A10A*, at the ﬁrst follow-up
year), the ﬁrst purchase date is included
trt  met  7 Num Number of metformin purchase dates (ATC = A10BA02, at the ﬁrst
follow-up year), the ﬁrst purchase is included
trt  oth 7 Num Number of other treatment purchase dates (ATC = A10B and
ATC = A10BA02, at the ﬁrst follow-up year), the ﬁrst purchase is included
diab1 5 Num 1 – probable type 1 diabetes; if 2 insulin purchases in ﬁrst year and
difference is 180 days or less AND no sulfonylureas (A10BB, A10BH,
A10BX) prescribed during 1st year; 0 – otherwise
Age  2 Num Baseline age = (ind1 dt − birth dt)/365.25
Use  of medicines
pt id 5 Num Patient masked ID
purch dt 8 Num Purchase date
pkgcount 8 Num Number of packages purchased
Atc 3 Char ATC code
pt cost 7 Num Patient co-payment (local units)
pay  cost 8 Num Payers cost (local units)
sum cost 8 Num Purchase total cost (local units)
ins  vol Num How many ml  of insulin 1 package contains, only for A10A prescriptions,
missing for other prescriptions
Hospital use
pt id 5 Num Patient masked ID
start dt 8 Num Date of start of hospital episode
end  dt 6 Num End date of hospital episode
inpat  5 Num Overnight stay present (1) or not present (0)
main dgn 8 Char ICD9/10 code
dgn2 8 Char First secondary diagnosis, if present
dgn3 8 Char Second secondary diagnosis, if present
.  . . 8 Char use this to mark the rest of secondary diagnosis
tot  cost 8 Num Total cost of hospitalization episode
hsp days 8 Num Total days in hospital (overnight stays)
spec 4 Char Speciality – standardized
d  mi  4 Num Myocardial infarction present (1) or not present (0)
d  stroke 8 Num Stroke present (1) or not present (0)
d  ret 5 Num Retinopathy present (1) or not present (0)
d  kidney 8 Num Chronic kidney disease present (1) or not present (0)
d  revasc 8 Num Coronary revascularization present (1) or not present (0)
d  catar 7 Num Cataract surgery present (1) or not present (0)
d  renal 7 Num End stage of renal disease present (1) or not (0)
d  amp  5 Num Leg amputation
d  hf 4 Num Heart failure
d  ihd 5 Num Ischemic heart disease
Out-patient (non-hospital physician visits)
pt  id 5 Num Patient masked ID
visit dt 8 Num Date of visit
main  dgn 8 Char Principal diagnosis, if present
dgn2 8 Char First secondary diagnosis, if present
dgn3 8 Char Second secondary diagnosis, if present
.  . . 8 Char use this to mark the rest of secondary diagnosis
spec 4 Char Speciality – standardized
tot  cost 8 Num Total cost if present (local units)
Lab  analysis (exclude lab tests results during hospital stay)
pt  id 5 Num Patient masked ID
lab dt 6 Num Date of analysis
provider 8 Char Provider, if present
result 6 Char Result, if present
lab cost 8 Num Cost, if present (local units)
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